TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: total number of all-causes catheter exchange
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fecal recovery of ingested salmon DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rapid gait speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minutes of moderate/vigorous physical activity (PA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: skinfold thicknesses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gain in mean clinical attachment level (CAL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in bacterial levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Test scores for the exotropia course
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference for flipped classroom over traditional classroom
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Modified Fatigue Impact Scale score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Cumulative treatment duration to achieve 1 SVR
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Adverse events (AEs) burden
Endpoint domain: Adverse events/effects
Primary endpoint: anxiety-related disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in Hb from baseline to study end
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of patients losing 5% or more of initial weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with T < 0.30 ng/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean plasma testosterone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Movement time improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in forced expiratory volume in 1 s
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Performance of 2-segment cardiac reconstruction algorithms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: fewer instrument adjustments
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: fewer CT scans
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: less CT fluoroscopy time
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Life Year (LY) gained
Endpoint domain: Mortality/survival
Primary endpoint: Quality-Adjusted Life Year (QALY) gained
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Request for rescue antiemetic
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reduction in TNSS (Total Nasal Symptom Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral corticosteroid dosage
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Interval from start of induction to vaginal delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Oxytocin augmentation of labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: HAM-D17 score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in penile circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in hamstring flexibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Symptom control rate
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: arrest rates
Endpoint domain: Mortality/survival
Primary endpoint: conviction of a felony
Endpoint domain: Mortality/survival
Primary endpoint: sentencing to incarceration and probation
Endpoint domain: Mortality/survival
Primary endpoint: Rate of local swelling and erythema at the administration site
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean concentration of anti‐H influenzae anticapsular antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency of antigenuria after vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: K-ARS total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean β value of the right frontal lobe
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Respiratory function variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Clinical symptoms of COPD patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surface morphology of residual dentin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of hsPDA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of antibiotic treatment costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reduction in the number of FRIDs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pooled protective efficacy of tafenoquine
Endpoint domain: Mortality/survival
Primary endpoint: Speech perception score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean umbilical artery pO(2) value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Induction to expulsion time of catheter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Remission (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Symptoms of complicated grief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total postoperative ibuprofen consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extra need for oral ibuprofen
Endpoint domain: Adverse events/effects
Primary endpoint: hemofilter survival time
Endpoint domain: Mortality/survival
Primary endpoint: Occurrence of gastrointestinal symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Use of analgesics/antipyretics
Endpoint domain: Resource use
Primary endpoint: Occurrence of respiratory symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of self-focused responses
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: PhNR amplitude increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Serum Lep levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum Adi contents
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Highest sensory blockade level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time to highest sensory blockade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of atropine use for bradycardia
Endpoint domain: Adverse events/effects
Primary endpoint: Episodes of P. carinii pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: ZBI scores improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in unmet needs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Global clinical score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Penetration force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduced negative life events
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Prevalence of wheezing during last 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: High-risk peptic ulcer bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Postprandial serum TAG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Plasma GLP-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Diarrhoea leading to treatment discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Tumour grade identification accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Microvascular invasion (MVI) identification accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: primary endpoint pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Complete lesion response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Excellent or good cosmetic outcome
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: maximally achieved power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nd: YAG laser capsulotomy rates
Endpoint domain: Adverse events/effects
Primary endpoint: Muscle protein synthesis (MPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Klotho protein level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FGF-23 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BNP level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 40% decrease in PANSS‐EC scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost of antiretrovirals
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reduction in inhaled glucocorticoid dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum SOFA coagulation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CHD incidence
Endpoint domain: Mortality/survival
Primary endpoint: IBS-SSS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean MSNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean SaO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma BNP levels at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: median percentage decrease in PSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subjective response at 3 months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Positive predictive value for severe injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiation exposure for less severely injured patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Restoring ovulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Normalizing important parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time to first analgesic requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportions of subjects with favorable OPS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Survival without grade 3/4 toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: remission in depressed children and adolescents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of HMPV in AE-COPD patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Improvement of aesthetic aspect of scar formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement of functional aspect of scar formation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improvement of emotional aspect of scar formation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement in sleeping problems
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: parasitemia half-life
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of radiation-induced diarrhea
Endpoint domain: Adverse events/effects
Primary endpoint: Mean time to use of loperamide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: CD4 cell count under 500 cells/mm3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Use of blood components
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Failure to control bleed
Endpoint domain: Adverse events/effects
Primary endpoint: Failure to prevent rebleed
Endpoint domain: Adverse events/effects
Primary endpoint: QALY differential
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: decreased pain severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improved general health status, quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Interventricular electrical delay (RV-LV-IED)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Distance between the acetabular component and the acetabular teardrop
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median plasma cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinical cure and improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eradication or presumed eradication of pathogens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Airway responsiveness to histamine and NKA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: perceived security in daily activities
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: pain complaints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arrest rates of root caries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30-day readmission
Endpoint domain: Adverse events/effects
Primary endpoint: S‐25OHD concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HOOS Jr score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Risk of lingual gingival recessions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: needle-to-balloon time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fluoroscopy time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CAK dose area product
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In-stent late lumen loss (LLL) at 9 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinically driven target lesion revascularization rates at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: breast cancer occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Technical success rate of filter placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of filter fracture
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of filter tilt
Endpoint domain: Adverse events/effects
Primary endpoint: psychosomatic self-regulation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: shorter illness duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fewer nights disturbed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: less paracetamol consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum IL-6 reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: serum iron status improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total Oxygen (TO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tachycardia Score (TS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reductions in psychiatric distress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emesis free status during the first 24 hours after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: knee score outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: general health outcome
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of opioid-negative urine drug tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of heroin
Endpoint domain: Adverse events/effects
Primary endpoint: Use of other illicit opioids
Endpoint domain: Adverse events/effects
Primary endpoint: myocardial MDA content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: SOD content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: time of heart self-recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of failed extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improve physical functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Fewer respiratory pauses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Fewer SpO2 declines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Fewer bradycardic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: bone fill percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subjective functional impairment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: DD scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance of microsporidia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Absorption of D‐xylose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of peripheral mononuclear cells expressing IL-2R alpha (CD25+)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: BTT score changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CCSIT score changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Locoregional control rates
Endpoint domain: Mortality/survival
Primary endpoint: adverse outcomes in infants with early stage 2 or 3 encephalopathy
Endpoint domain: Adverse events/effects
Primary endpoint: Response times on the complex level of the Stroop test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Response times on the five item level of the Sternberg paradigm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Incidence of reexploration for neck hematoma
Endpoint domain: Adverse events/effects
Primary endpoint: Ipsilateral stroke-free rates
Endpoint domain: Mortality/survival
Primary endpoint: Freedom from ≥70% carotid restenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: ALT levels
Endpoint domain: Adverse events/effects
Primary endpoint: BGT (Blood Glucose Test)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of taste disturbance
Endpoint domain: Adverse events/effects
Primary endpoint: Overall assessment of tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: THC Cmax concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: scatter radiation exposure reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in PASAT‐3 score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Short Form-36 scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: ACR/KAOS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average phoneme score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intention to use doping drugs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perception of being able to refuse doping
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Estimated 2-year DFS
Endpoint domain: Mortality/survival